West Pharma (WST) Tops Q1 EPS by 45c, provides guidance

West Pharma (NYSE: WST) reported Q1 EPS of $2.13, $0.45 better than the analyst estimate of $1.68. Revenue for the quarter came in at $844.9 million versus the consensus estimate of $780.65 million.

GUIDANCE:

West Pharma sees FY2026 EPS of $8.40-$8.75, versus the consensus of $8.01. West Pharma sees FY2026 revenue of $3.295-3.35 billion, versus the consensus of $3.249 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Vicor raises Q3 2026 revenue guidance on new licensing deal
• Bloomia Holdings, Inc. Announces June 30, 2026 Financial Results
• StoneX Reiterates Buy Rating on Criteo S.A. (CRTO) as Open AI Integration Shows Encouraging Early Signals